Status check: Novo Nordisk's $675 list price still lands well above every negotiated and cash price

Novo Nordisk's plan to cut the US list price of its semaglutide medicines to $675 a month takes effect on January 1, 2027 ^[1][2]. Nearly seven months after the February 24, 2026 announcement, the basic math has not changed: $675 is a large drop from where these drugs started, but it remains well above the cash prices Novo already offers and above the government-set prices that apply in other channels.

What the $675 price is, and isn't

The new list price applies to Wegovy, Ozempic and Rybelsus — all semaglutide — at $675 for a one-month supply of each ^[1][2]. Novo says the covered doses include the 2.4 mg Wegovy injection, 25 mg Wegovy tablets, the 0.5 mg, 1 mg and 2 mg Ozempic injections, and Rybelsus 7 mg to 14 mg tablets ^[1].

All three currently carry list prices above $1,000 a month, with Wegovy injections and pills the most expensive at $1,349 ^[2]. That works out to a cut of roughly half for Wegovy and about a third for Ozempic.

The company was explicit that this is a list-price change only. Prices in its direct-to-consumer portal are not changing ^[1]. Novo had already lowered the cash price for injectable Wegovy and most Ozempic doses to $349 a month, down from $499, for people buying directly from the drugmaker, its telehealth partners, or retail pharmacies ^[2]. In other words, the "new lower price" is still nearly double the existing cash price for the same medicine.

Other prices in the market — including federal most-favored-nation pricing and the Medicare negotiated maximum fair price for semaglutide — have been reported as lower than both figures, but the exact amounts are not documented in the sources reviewed for this article, so treat specific dollar figures for those programs as not confirmed here.

Why it matters for patients

List price is the sticker number, not what most insured people pay. It matters most for two groups. The first is people with coinsurance, who pay a percentage of the drug's overall cost rather than a flat copay. The second is people in high-deductible plans, who pay the full negotiated amount until the deductible is met ^[1][2]. Novo Nordisk US president Jamey Millar said the lower list price is "intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs" ^[1].

If you pay cash today, the announcement changes nothing about your bill ^[2]. If your plan covers the drug with a fixed copay, it probably changes little either.

Cost is already driving treatment decisions. A Navitus Health Solutions–commissioned survey of nearly 2,000 people, released February 24, 2026, found about 7 in 10 people who had taken GLP-1 medications said cost influenced their decision to start or continue treatment, and 1 in 4 paid more than $250 for every fill ^[2].

Coverage remains uneven. A Mercer survey found 49% of large employers covered GLP-1 medications in 2025, up from 41% in 2023, while KFF found 43% of larger employers paid for anti-obesity drugs in 2025 ^[2]. Employers are generally more willing to cover diabetes use than weight-loss use ^[2].

What happens next

Novo announced the change more than 10 months ahead of time partly so employers and insurers could build benefits around it, Millar said ^[2]. That means plan designs for the 2027 benefit year are where the effect, if any, will show up.

Competition is also shifting. Eli Lilly disclosed a $1.5 billion pre-launch inventory of orforglipron, a pill, ahead of an anticipated FDA decision ^[1]. Novo's CagriSema produced 23% weight reduction over 84 weeks versus 25.5% for tirzepatide in a head-to-head trial reported February 23, 2026; Novo expects an FDA decision by the end of 2026 and a 2027 launch ^[2]. Whether more competition pushes real out-of-pocket costs below $675 is not yet known.